Health System

Over the Counter: The "Disruptors" and the Role of Innovation in Drug Pricing

September 17, 2020

Eric Levin, CEO of Scripta Insights, discusses how "positive disruption" from private companies are positioned to confront challenges within the pharmaceutical industry.

Boston Medical Center Reduces Opioid Use in Surgical Patients

September 17, 2020

Pharmacists, nurses, and physicians work together to combat the overuse of powerful pain relievers.

Baricitinib Plus Remdesivir Improves Recovery Time for Hospitalized COVID-19

September 15, 2020

Early data from a phase 3 trial showed that baricitinib combined with remdesivir improved recovery in patients hospitalized with COVID-19 compared with remdesivir alone.

FDA Alert: Efficacy Concerns with Atezolizumab Plus Paclitaxel for Breast Cancer

September 11, 2020

The FDA issued a safety alert about efficacy and potential safety concerns with a combination therapy being studied for the treatment of breast cancer.

Oncology Pharmacists Adapt to Serve Patients Amid Pandemic

September 10, 2020

Oncology pharmacists have implemented new ways to communicate with patients, schedule visits and treatments, and re-evaluate their medications regimens during the pandemic.

Coronavirus News Roundup: FDA Issues EUA for Rapid Antigen Test, ASHP Releases COVID-19 Vaccine Guidelines

August 28, 2020

Here's the coronavirus-related news from this week that you should know.

ASHP Outlines Tenets for COVID-19 Vaccine Rollout and Oversight

August 27, 2020

ASHP issued its recommended principles for the development, distribution, allocation, and oversight of an eventual COVID-19 vaccine.

FDA Removes Boxed Warning for Amputation Risk From Canagliflozin

August 27, 2020

The removal of the boxed warning from canagliflozin was based on the FDA’s review of new data from 3 clinical trials.

Amisulpride Injection Now Available in the US for Postoperative Nausea and Vomiting

August 25, 2020

Amisuplride injection (Barhemsys; Acacia) is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed prior prophylaxis with an agent of a different class.